Exelixis (EXEL) traded lower Friday as the latest incremental pressure came from a recent analyst reset: RBC Capital reduced its price target to $43 while keeping a neutral-style stance (Sector Perform), reinforcing the market’s view that near-term upside may be limited until the next major clinical and regulatory milestones arrive. (insidermonkey.com)

With Cabometyx as the core revenue engine, sentiment is highly sensitive to the durability of the franchise and the credibility of Exelixis’ push to build a second growth pillar around zanzalintinib. Investor attention has increasingly centered on the ongoing regulatory path for zanzalintinib in metastatic colorectal cancer, where the FDA target action date is December 3, 2026—making the stock especially prone to repositioning and de-risking on down-market biotech days. (investing.com)

The next potential re-rating catalysts are expected around mid-2026 as Exelixis works through planned pivotal readouts and program progress updates, including further updates tied to the STELLAR clinical program. Until those arrive, price action can be driven by analyst notes, sector risk appetite, and any incremental signals about commercialization expectations and timeline confidence for the 2026 decision point. (ir.exelixis.com)